Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2009 1
2010 2
2011 2
2014 1
2015 1
2016 1
2017 2
2018 1
2019 3
2020 7
2021 6
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants.
Logue J, Johnson RM, Patel N, Zhou B, Maciejewski S, Foreman B, Zhou H, Portnoff AD, Tian JH, Rehman A, McGrath ME, Haupt RE, Weston SM, Baracco L, Hammond H, Guebre-Xabier M, Dillen C, Madhangi M, Greene AM, Massare MJ, Glenn GM, Smith G, Frieman MB. Logue J, et al. Among authors: massare mj. Nat Commun. 2023 Feb 28;14(1):1130. doi: 10.1038/s41467-022-35606-6. Nat Commun. 2023. PMID: 36854666 Free PMC article.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Bangaru S, et al. Among authors: massare mj. Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502. Epub 2020 Oct 20. Science. 2020. PMID: 33082295 Free PMC article.
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Logue J, Portnoff AD, Norton J, Guebre-Xabier M, Zhou B, Jacobson K, Maciejewski S, Khatoon R, Wisniewska M, Moffitt W, Kluepfel-Stahl S, Ekechukwu B, Papin J, Boddapati S, Jason Wong C, Piedra PA, Frieman MB, Massare MJ, Fries L, Bengtsson KL, Stertman L, Ellingsworth L, Glenn G, Smith G. Tian JH, et al. Among authors: massare mj. Nat Commun. 2021 Jan 14;12(1):372. doi: 10.1038/s41467-020-20653-8. Nat Commun. 2021. PMID: 33446655 Free PMC article.
Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine.
Shinde V, Fries L, Wu Y, Agrawal S, Cho I, Thomas DN, Spindler M, Lindner E, Hahn T, Plested J, Flyer D, Massare MJ, Zhou B, Fix A, Smith G, Glenn GM. Shinde V, et al. Among authors: massare mj. N Engl J Med. 2018 Jun 14;378(24):2346-2348. doi: 10.1056/NEJMc1803554. N Engl J Med. 2018. PMID: 29897849 Free article. No abstract available.
Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
Shinde V, Cho I, Plested JS, Agrawal S, Fiske J, Cai R, Zhou H, Pham X, Zhu M, Cloney-Clark S, Wang N, Zhou B, Lewis M, Price-Abbott P, Patel N, Massare MJ, Smith G, Keech C, Fries L, Glenn GM. Shinde V, et al. Among authors: massare mj. Lancet Infect Dis. 2022 Jan;22(1):73-84. doi: 10.1016/S1473-3099(21)00192-4. Epub 2021 Sep 23. Lancet Infect Dis. 2022. PMID: 34563277 Clinical Trial.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Bangaru S, et al. Among authors: massare mj. bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.234674. doi: 10.1101/2020.08.06.234674. bioRxiv. 2020. PMID: 32793901 Free PMC article. Updated. Preprint.
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman MJ, Patel N, Guebre-Xabier M, Zhu AL, Atyeo C, Pullen KM, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH, Yuan D, Bowman KA, Zhou B, Maciejewski S, McGrath ME, Logue J, Frieman MB, Montefiori D, Mann C, Schendel S, Amanat F, Krammer F, Saphire EO, Lauffenburger DA, Greene AM, Portnoff AD, Massare MJ, Ellingsworth L, Glenn G, Smith G, Alter G. Gorman MJ, et al. Among authors: massare mj. Cell Rep Med. 2021 Sep 21;2(9):100405. doi: 10.1016/j.xcrm.2021.100405. Epub 2021 Aug 31. Cell Rep Med. 2021. PMID: 34485950 Free PMC article.
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation.
Plested JS, Zhu M, Cloney-Clark S, Massuda E, Patel U, Klindworth A, Massare MJ, Cai R, Fries L, Glenn G, Kalkeri R. Plested JS, et al. Among authors: massare mj. Microorganisms. 2023 Feb 1;11(2):368. doi: 10.3390/microorganisms11020368. Microorganisms. 2023. PMID: 36838333 Free PMC article.
27 results